Psychological and ethical considerations in screening for disease

Kimberly A. Quaid

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Coronary artery disease is the leading cause of death in the United States. Serum cholesterol is a widely used screening test to detect persons at high risk for coronary artery disease, including those with familial hypercholesterolemia. However, universal screening of currently healthy persons is not without risk. Previous experience in screening for sickle cell anemia and hypertension has shown that these risks include misunderstanding of test results, misdiagnosis, labeling, stigmatization, and decreased psychological well-being. Results of screening programs may be misused by industry or insurance companies to exclude individuals from positions or benefits. Consideration of these harms suggests that screening should not be implemented until certain safeguards are in place. Physicians and the public should be educated about the potential risks and benefits of screening. Screening tests should be accurate, reliable, valid, and of demonstrated sensitivity. Informed consent for screening should be obtained. Follow-up surveillance and recommended treatments, including dietary counseling and drug therapy, should be available to all individuals identified as being at high risk regardless of their socioeconomic status. Finally, procedures to protect the right to privacy of individuals and their families should be implemented well in advance of the actual screening.

Original languageEnglish
JournalThe American Journal of Cardiology
Volume72
Issue number10
DOIs
StatePublished - Sep 30 1993

Fingerprint

Psychology
Coronary Artery Disease
Stereotyping
Hyperlipoproteinemia Type II
Privacy
Sickle Cell Anemia
Insurance
Diagnostic Errors
Informed Consent
Social Class
Counseling
Cause of Death
Industry
Cholesterol
Hypertension
Physicians
Drug Therapy
Serum
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Psychological and ethical considerations in screening for disease. / Quaid, Kimberly A.

In: The American Journal of Cardiology, Vol. 72, No. 10, 30.09.1993.

Research output: Contribution to journalArticle

@article{05bbb416646947e7ab115dd23561627f,
title = "Psychological and ethical considerations in screening for disease",
abstract = "Coronary artery disease is the leading cause of death in the United States. Serum cholesterol is a widely used screening test to detect persons at high risk for coronary artery disease, including those with familial hypercholesterolemia. However, universal screening of currently healthy persons is not without risk. Previous experience in screening for sickle cell anemia and hypertension has shown that these risks include misunderstanding of test results, misdiagnosis, labeling, stigmatization, and decreased psychological well-being. Results of screening programs may be misused by industry or insurance companies to exclude individuals from positions or benefits. Consideration of these harms suggests that screening should not be implemented until certain safeguards are in place. Physicians and the public should be educated about the potential risks and benefits of screening. Screening tests should be accurate, reliable, valid, and of demonstrated sensitivity. Informed consent for screening should be obtained. Follow-up surveillance and recommended treatments, including dietary counseling and drug therapy, should be available to all individuals identified as being at high risk regardless of their socioeconomic status. Finally, procedures to protect the right to privacy of individuals and their families should be implemented well in advance of the actual screening.",
author = "Quaid, {Kimberly A.}",
year = "1993",
month = "9",
day = "30",
doi = "10.1016/0002-9149(93)90013-3",
language = "English",
volume = "72",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Psychological and ethical considerations in screening for disease

AU - Quaid, Kimberly A.

PY - 1993/9/30

Y1 - 1993/9/30

N2 - Coronary artery disease is the leading cause of death in the United States. Serum cholesterol is a widely used screening test to detect persons at high risk for coronary artery disease, including those with familial hypercholesterolemia. However, universal screening of currently healthy persons is not without risk. Previous experience in screening for sickle cell anemia and hypertension has shown that these risks include misunderstanding of test results, misdiagnosis, labeling, stigmatization, and decreased psychological well-being. Results of screening programs may be misused by industry or insurance companies to exclude individuals from positions or benefits. Consideration of these harms suggests that screening should not be implemented until certain safeguards are in place. Physicians and the public should be educated about the potential risks and benefits of screening. Screening tests should be accurate, reliable, valid, and of demonstrated sensitivity. Informed consent for screening should be obtained. Follow-up surveillance and recommended treatments, including dietary counseling and drug therapy, should be available to all individuals identified as being at high risk regardless of their socioeconomic status. Finally, procedures to protect the right to privacy of individuals and their families should be implemented well in advance of the actual screening.

AB - Coronary artery disease is the leading cause of death in the United States. Serum cholesterol is a widely used screening test to detect persons at high risk for coronary artery disease, including those with familial hypercholesterolemia. However, universal screening of currently healthy persons is not without risk. Previous experience in screening for sickle cell anemia and hypertension has shown that these risks include misunderstanding of test results, misdiagnosis, labeling, stigmatization, and decreased psychological well-being. Results of screening programs may be misused by industry or insurance companies to exclude individuals from positions or benefits. Consideration of these harms suggests that screening should not be implemented until certain safeguards are in place. Physicians and the public should be educated about the potential risks and benefits of screening. Screening tests should be accurate, reliable, valid, and of demonstrated sensitivity. Informed consent for screening should be obtained. Follow-up surveillance and recommended treatments, including dietary counseling and drug therapy, should be available to all individuals identified as being at high risk regardless of their socioeconomic status. Finally, procedures to protect the right to privacy of individuals and their families should be implemented well in advance of the actual screening.

UR - http://www.scopus.com/inward/record.url?scp=0027377974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027377974&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(93)90013-3

DO - 10.1016/0002-9149(93)90013-3

M3 - Article

C2 - 8213500

AN - SCOPUS:0027377974

VL - 72

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10

ER -